Samsung Bioepis announced on the 15th that it has signed a marketing partnership with Yuhan for domestic sales of Adalloce, biosimilar for Humira.

Adalloce is a biosimilar of Adalimuma with the largest global sales. It was the first in Korea to be approved for sale among the biosimilars for Adalimuma. It treats autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease through a mechanism that suppresses the expression of tumor necrosis factor (TNF-α) in the body.

Samsung Bioepis obtained a marketing license for Adalloce from the MFDS in September 2017, and has been preparing for domestic release through a licensing agreement with AbbVie, an original de